- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Reviva announces pricing of $18M public offering of common stock and warrants | 12 | Seeking Alpha | ||
| Mo | Reviva Pharmaceuticals: Reviva Announces Proposed Public Offering | 3 | GlobeNewswire (USA) | ||
| Mo | Reviva's antipsychotic shows promise against schizophrenia symptoms in year-long study | 2 | FierceBiotech | ||
| Mo | Reviva reports positive 1-year schizophrenia drug trial data | 3 | Investing.com | ||
| REVIVA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 12.12. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 5 | SEC Filings | ||
| 14.11. | Reviva Pharmaceuticals: Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights | 167 | GlobeNewswire (Europe) | - 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial - - Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine's improvement on negative... ► Artikel lesen | |
| 14.11. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 12.11. | Reviva vermeldet Fortschritte bei Studie zur Schizophrenie-Behandlung | 4 | Investing.com Deutsch | ||
| 08.10. | Reviva Pharmaceuticals: Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit | 1 | GlobeNewswire (USA) | ||
| 07.10. | Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst | 32 | Benzinga.com | ||
| 02.10. | Reviva Pharmaceuticals: Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference | 3 | GlobeNewswire (USA) | ||
| 26.09. | Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference | 1 | GlobeNewswire (USA) | ||
| 23.09. | EF Hutton setzt Kaufempfehlung für Reviva Pharmaceuticals-Aktien | - | Investing.com Deutsch | ||
| 23.09. | EF Hutton sets Buy rating on Reviva Pharmaceuticals shares | 1 | Investing.com | ||
| 17.09. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.09. | Reviva Pharmaceuticals: Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia | 292 | GlobeNewswire (Europe) | - Statistically significant vocal biomarker speech latency data reinforce the strong efficacy of brilaroxazine for negative symptoms and other key symptom domains of schizophrenia - - Additional vocal... ► Artikel lesen | |
| 21.08. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.08. | Reviva Pharmaceuticals stock falls after it prices $5M offering | 1 | Seeking Alpha | ||
| 21.08. | Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules | 2 | GlobeNewswire (USA) | ||
| 15.08. | Reviva Pharmaceuticals GAAP EPS of -$0.26 | 3 | Seeking Alpha |
Seite:
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIATRIS | 11,970 | -0,33 % | Kaum Impulse für die Viatris-Aktie (12,0044 €) | Der Kurs der dem Anteilsschein von Viatris kommt kaum von der Stelle. Der jüngste Kurs betrug 12,60 US-Dollar. Der Kurs der Aktie von Viatris zeigt sich zur Stunde kaum verändert im Vergleich zu der... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 7,500 | -0,86 % | Multi-Bagger entdeckt!: Der europäische Cannabissektor wird in den nächsten Jahren auf 24 Mrd. $ explodieren - diese Aktie profitiert! | ||
| ASTRIA THERAPEUTICS | 9,560 | +1,16 % | Astria Therapeutics, Inc. - 8-K, Current Report | ||
| TONIX PHARMACEUTICALS | 0,609 | +6,81 % | What's Going On With Tonix Pharmaceuticals Stock Today? | ||
| CASSAVA SCIENCES | 2,249 | -0,40 % | XFRA PX91: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| NEWRON PHARMACEUTICALS | 8,790 | +0,23 % | Community Rückblick: wO User zu Newron Lizenzvereinbarung mit EA Pharma: "Unheimlich guter Deal!" | © Foto: Gorodenkoff / Stock.adobe.comDie Diskussion um Newron Pharma explodierte, nachdem die italienische Biotechfirma am 13.12. die Kooperation mit "EA-Pharma" aus Japan, zum Vertrieb des Hoffnungsmittels... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 0,874 | -1,41 % | Nektar's NKTR-255 After CD19 CAR-T Therapy Enhances Complete Response In R/R Large B-Cell Lymphoma | WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR) announced results of its Phase 2 proof-of-concept study, which evaluated NKTR-255 as an adjuvant treatment to enhance complete response rate... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 2,330 | +2,28 % | ORAMED PHARMACEUTICALS INC. - 8-K, Current Report | ||
| ROCKET LAB USA | 23,900 | 0,00 % | Space Technology: Rocket Lab stellt zweites Raumfahrzeug für Varda Space Industries fertig | ||
| COMPASS PATHWAYS | 3,860 | +1,58 % | Compass Pathways plc: Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI) | Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today its common stock will be added... ► Artikel lesen | |
| OPUS GENETICS | 1,028 | +7,76 % | Opus Genetics, Inc.: Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy | Agreement Reached on Primary Endpoint and Phase 3 Trial Design Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering FARMINGTON HILLS, Mich., Dec. 19, 2024 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 8,826 | +1,87 % | Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS Growth and AUR200 Development | ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the third quarter and nine months... ► Artikel lesen | |
| SCYNEXIS | 0,957 | -1,34 % | SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections | JERSEY CITY, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant... ► Artikel lesen | |
| LIPOCINE | 4,800 | +2,56 % | Lipocine Inc.: FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis | SALT LAKE CITY, Dec. 17, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment... ► Artikel lesen | |
| BOIRON | 26,600 | -0,19 % | BOIRON: EVOLUTION OF GOVERNANCE | July 3rd, 2024
The Board of Directors of Laboratoires BOIRON, meeting today under the chairmanship of Thierry BOIRON, has enacted an evolution of the Group's governance.
In this context, Thierry... ► Artikel lesen |
REVIVA PHARMACEUTICALS HOLDINGS INC gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von -0,165 (-11,00 %) liegt der Kurs bei 1,335 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVIVA PHARMACEUTICALS HOLDINGS INC finden Sie auf Wallstreet Online.
